JP2025508380A - Ｂ７－ｈ４抗体薬物複合体を含む、癌の処置のための組み合わせ療法 - Google Patents

Ｂ７－ｈ４抗体薬物複合体を含む、癌の処置のための組み合わせ療法 Download PDF

Info

Publication number
JP2025508380A
JP2025508380A JP2024547662A JP2024547662A JP2025508380A JP 2025508380 A JP2025508380 A JP 2025508380A JP 2024547662 A JP2024547662 A JP 2024547662A JP 2024547662 A JP2024547662 A JP 2024547662A JP 2025508380 A JP2025508380 A JP 2025508380A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508380A5 (https=
Inventor
レオ，エリザベッタ
アンネ トスト，フランシス
リン キニア，クリスタ
クック，キンバリー
チーズブロー，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2025508380A publication Critical patent/JP2025508380A/ja
Publication of JP2025508380A5 publication Critical patent/JP2025508380A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024547662A 2022-02-16 2023-02-15 Ｂ７－ｈ４抗体薬物複合体を含む、癌の処置のための組み合わせ療法 Pending JP2025508380A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263310967P 2022-02-16 2022-02-16
US63/310,967 2022-02-16
US202263378295P 2022-10-04 2022-10-04
US63/378,295 2022-10-04
PCT/EP2023/053720 WO2023156434A1 (en) 2022-02-16 2023-02-15 Combination therapies for treatment of cancer comprising b7-h4 antibody drug conjugate

Publications (2)

Publication Number Publication Date
JP2025508380A true JP2025508380A (ja) 2025-03-26
JP2025508380A5 JP2025508380A5 (https=) 2026-02-24

Family

ID=85283493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547662A Pending JP2025508380A (ja) 2022-02-16 2023-02-15 Ｂ７－ｈ４抗体薬物複合体を含む、癌の処置のための組み合わせ療法

Country Status (13)

Country Link
US (1) US20230310636A1 (https=)
EP (1) EP4479428A1 (https=)
JP (1) JP2025508380A (https=)
KR (1) KR20240150781A (https=)
AU (1) AU2023221516A1 (https=)
CA (1) CA3250868A1 (https=)
CL (1) CL2024002434A1 (https=)
CO (1) CO2024012148A2 (https=)
CR (1) CR20240385A (https=)
IL (1) IL314797A (https=)
MX (1) MX2024009972A (https=)
TW (1) TW202348252A (https=)
WO (1) WO2023156434A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103407A1 (zh) * 2023-11-16 2025-05-22 江苏豪森药业集团有限公司 抗体药物偶联物和多腺苷二磷酸核糖聚合酶抑制剂的联合应用
TW202539742A (zh) * 2024-02-08 2025-10-16 大陸商上海翰森生物醫藥科技有限公司 抗體藥物偶聯物和抗ｖｅｇｆ抗體的聯合應用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016040724A1 (en) * 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
EP3612567B1 (en) * 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
MX2021011812A (es) 2019-03-29 2021-10-22 Medimmune Ltd Compuestos y conjugados de estos.
SI3999506T1 (sl) 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1
BR112023004415A2 (pt) 2020-09-11 2023-05-09 Medimmune Ltd Moléculas terapêuticas de ligação a b7-h4

Also Published As

Publication number Publication date
IL314797A (en) 2024-10-01
KR20240150781A (ko) 2024-10-16
US20230310636A1 (en) 2023-10-05
MX2024009972A (es) 2024-08-26
CR20240385A (es) 2024-10-16
WO2023156434A1 (en) 2023-08-24
AU2023221516A1 (en) 2024-09-19
CA3250868A1 (en) 2023-08-24
TW202348252A (zh) 2023-12-16
CL2024002434A1 (es) 2024-11-08
CO2024012148A2 (es) 2024-09-30
EP4479428A1 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
JP2024102229A (ja) 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート
JP5778700B2 (ja) フォレート受容体１抗体及びそのイムノコンジュゲート及び使用
US20180243435A1 (en) Anti-dll3 antibody drug conjugates and methods of use
JP6898925B2 (ja) Ａｓｃｔ２特異的結合分子及びその使用
JP2019069983A (ja) 新規抗体コンジュゲートおよびその使用
EP3774910A1 (en) Trispecific binding molecules against cancers and uses thereof
CN116059395A (zh) 用于选择性制造抗体-药物缀合物的方法
JP2020503258A (ja) Ａｓｃｔ２特異的結合分子及びその使用
TW202108178A (zh) 使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
JP2019506136A (ja) 新規抗ｅｍｒ２抗体及び使用方法
JP2024088757A (ja) Ｐｍｅｌ１７に対する抗体及びその結合体
JP2019534267A (ja) 抗ｃ ｍｅｔ抗体‐細胞傷害性薬物複合体の医学的使用
JP2025508380A (ja) Ｂ７－ｈ４抗体薬物複合体を含む、癌の処置のための組み合わせ療法
US20190127476A1 (en) Novel anti-tnfrsf21 antibodies and methods of use
WO2017112811A1 (en) Novel anti-tnfsf9 antibodies and methods of use
WO2024219442A1 (ja) 抗体－薬物コンジュゲートと他の薬剤との組み合わせ
CN118715245A (zh) 包含b7-h4抗体药物缀合物的用于治疗癌症的组合疗法
US20250051463A1 (en) Cd123 antibody-drug conjugates and methods of using the same
BR122021021119B1 (pt) Anticorpos anti-egfr, conjugado anticorpo-fármaco, composição farmacêutica, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido
BR112016021717B1 (pt) Anticorpos anti-egfr, conjugado anticorpo-fármaco, composição farmacêutica, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido
BR122024015645B1 (pt) Anticorpo anti-egfr, conjugado anticorpo-fármaco que compreende o dito anticorpo, composição farmacêutica compreendendo os mesmos, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido
BR122024015645A2 (pt) Anticorpos anti-egfr, conjugado anticorpo-fármaco, composição farmacêutica, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido, bem como ácido nucleico, vetor e célula hospedeira

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260213